• Deep-Sequencing Reveals Broad Subtype-Specific HCV Resistance Mutations Associated with Treatment Failure 

      Chen, Qian; Perales, Celia; Soria, María Eugenia; García-Cehic, Damir; Gregori, Josep; Rodríguez-Frías, Francisco; Buti, M.; Crespo, Javier; Calleja, J.L.; Tabernero, David; Vila Salvador, Marta; Lázaro, Fernando; Rando-Segura, Ariadna; Nieto-Aponte, Leonardo; Llorens-Revull, Meritxell; Cortese, Maria Francesca; Fernández, Irati; Castellote, José; Niubó, Jordi; Imaz, Arkaitz; Delgado, Manuel; Cañizares, Angelina; Castro-Iglesias, Ángeles (Elsevier, 2019-12-16)
      [Abstract] A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was ...
    • Influence of drug–drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus 

      Margusino-Framiñán, Luis; Cid-Silva, Purificación; Giménez-Arufe, Víctor; Mondelo-García, Cristina; Fernández-Oliveira, Carla; Mena, Álvaro; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (BMJ, 2019-06-13)
      [Abstract] Objectives Direct-acting antivirals are the recommended treatment for hepatitis C-infected patients. Drug–drug interactions with concomitant treatments can cause lack of effectiveness and/or safety. The objective ...
    • Update on hepatitis C virus resistance to direct-acting antiviral agents 

      Poveda, Eva; Wyles, David L.; Mena, Álvaro; Pedreira, José D.; Castro-Iglesias, Ángeles; Cachay, Edward (Elsevier, 2014-06-06)
      [Abstract] Resistance to direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) infection is driven by the selection of mutations at different positions in the NS3 protease, NS5B polymerase and NS5A proteins. ...